- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01716962
Effects of Positive End-expiratory Pressure and Tidal Volume on Fluid Responsiveness of Acute Respiratory Distress Syndrome
Effects of Positive End-expiratory Pressure and Tidal Volume on Fluid Responsiveness of Acute Respiratory Distress Syndrome.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In septic critically ill mechanically ventilated patients with acute circulatory failure, inadequate volume resuscitation leads to multiple organ failure. Early goal-directed therapy emphasizes early and aggressive hemodynamic support in patients with severe sepsis and septic shock. On the other hand, because of increased microvascular permeability and capillary leakage, conservative fluid management and more aggressive restriction in fluid accumulation to reduce lung water and tissue edema has been suggested by acute respiratory distress syndrome net. Fluid responsiveness refers to the ability of the heart to increase its stroke volume in response to volume load. Accurately predicting volume responsiveness will be beneficial in obviating the need for unnecessary fluid loading, and in detecting patients who may benefit from a volume load.
By inducing cyclic changes in pleural and transpulmonary pressure, mechanical ventilation results in cyclic changes in the preload and afterload, and therefore, the cyclic variation in systolic and pulse pressure. Recently, a systemic review concluded that dynamic preload indicator [pulse pressure variation (PPV), stroke volume variation (SVV)] are highly accurate in predicting volume responsiveness in critically ill patients. However, this technique is limited to patients who receive controlled ventilation with adequate tidal volume (> 8 ml/Kg) and sedation or paralysis is needed to abolish the spontaneous ventilation.
For acute respiratory distress syndrome patients, protective ventilatory strategy suggested low tidal volume to 6 ml/Kg. On the contrary, high PEEP needed for acute respiratory distress syndrome to prevent VALI induces a leftward shift to the steep pat of the Frank-Starling curve and increase the fluid responsiveness. Whether the dynamic preload indicators (PPV and SVV) are still effective in acute respiratory distress syndrome patients for predicting fluid responsiveness remain controversial.
Passive leg raising (PLR), by inducing a gravitational transfer of blood from the lower part of the body toward the central circulatory compartment, can be considered as a brief "self volume challenge". Recently, a systemic review and meta-analysis concluded that PLR-induced changes in cardiac output reliably predict fluid responsiveness regardless of ventilation mode, underlying cardiac rhythm and technique of measurement and can be recommended for routine assessment of fluid responsiveness in the majority of ICU population. More importantly, this prediction remains very valuable in patients with cardiac arrhythmias or spontaneous breathing activity.
Respiratory variations in the pulse oximeter plethysmographic waveform amplitude (ΔPOP) have been shown to be able to predict fluid responsiveness in mechanically ventilated patients. The main advantage of this index is that it is noninvasive, widely available, and inexpensive. Perfusion index (PI), the percentage between the infrared pulsatile and nonpulsatile signal, reflects the amplitude of the pulse oximeter waveform. Recently, Pleth Variability Index (PVI), derived from perfusion index, affords a continuous monitoring of ΔPOP. PVI has been shown to be correlated to ΔPOP and PPV and has been demonstrated to be equivalent to SVV as a predictor of fluid responsiveness in ventilated patients during major surgery. However, whether the PVI can predict the fluid responsiveness in acute respiratory distress syndrome necessitating low tidal volume and high PEEP is not clear.
Because of the aforementioned contrasting effects of low tidal volume and high PEEP on the prediction of fluid responsiveness, the aim of this study is to compare the relative predicting power of the dynamic preload indicator (PPV, SVV), passive leg raising test, and PVI on the fluid responsiveness of acute respiratory distress syndrome ventilated with various PEEP levels or various tidal volumes.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 10507
- Chang Gung Memorial Hospital
-
Sub-Investigator:
- Kuo-Chin Kao, MD
-
Contact:
- Chung-Chi Huang, MD
- Phone Number: 2281 033281200
- Email: cch4848@adm.cgmh.org.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria: Clinical signs of inadequate tissue perfusion were defined
- systolic blood pressure< 9 mmHg(or a decrease > 50 mmHg in previously hypertensive patients)
- need of vasopressive drugs(dopamine > 5 ug/Kg/min or norepinephrine)
- urine output<0.5 mL/Kg/hr for at least 2 hrs
- tachycardia (heart rate >100/min)
- presence of skin mottling.
Exclusion Criteria:
- patient with spontaneous respiratory activity
- cardiac arrhythmia
- known intracardiac shunt
- contraindication for passive leg raising(PLR),e.g.,pelvic trauma
- unstable spine injuries or leg amputation
- hemodynamic instability during the procedure,defined by a variation in heart rate or blood pressure of>10%over the 15-min period before starting the protocol
- Patients of renal failure necessitate renal replacement therapy will be excluded also.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
ARDS with acute circulatory failure
acute respiratory distress syndrome with acute circulatory failure with infusion of 6% tetrastarch for a total of 500ml
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
increase of cardiac output after volume expansion
Time Frame: 4 hours
|
Patients are classified to be volume expansion responders or nonresponders according to whether the volume expansion induced cardiac index increase at the end of hydroxyethyl starch infusion is ≧15% or < 15% of baseline cardiac index.
|
4 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chung-Chi Huang, MD, Chang Gung Memorial Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CGMF IRB 100-4473A3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Distress Syndrome, Adult
-
Centre Hospitalier Universitaire de NiceCompletedRespiratory Distress Syndrome,AdultFrance
-
Abbott NutritionTerminatedAcute Lung Injury | Respiratory Distress Syndrome,AdultRussian Federation
-
Wolfson Medical CenterUnknown
-
GlaxoSmithKlineTerminatedLung Injury, Acute and Respiratory Distress Syndrome, AdultUnited Kingdom
-
Amazon UniversitySanta Casa de Misericórdia do ParáCompletedSepsis | HELLP Syndrome | Postpartum Period | Respiratory Distress Syndrome,Adult
-
Michael A. MatthayMassachusetts General Hospital; National Heart, Lung, and Blood Institute (NHLBI) and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Chinese PLA General HospitalGeneral Hospital of Chinese Armed Police Forces; Beijing Shijitan Hospital,... and other collaboratorsUnknownAcute Lung Injury | Respiratory Distress Syndrome, AdultChina
-
Michael A. MatthayThe University of Texas Health Science Center, Houston; United States Department... and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Faron Pharmaceuticals LtdSeventh Framework ProgrammeTerminatedRespiratory Distress Syndrome, AdultSpain, United Kingdom, France, Italy, Finland, Czechia, Belgium, Germany
-
Karolinska University HospitalKarolinska InstitutetUnknownAcute Respiratory Distress Syndrome, AdultSweden
Clinical Trials on Infusion of 6% tetrastarch for a total of 500 ml
-
Montefiore Medical CenterSuspendedBronchopulmonary Dysplasia | Prone PositioningUnited States
-
Frederiksberg University HospitalUnknown
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Leonardo ClavijoAmgenUnknownPeripheral Arterial DiseaseUnited States
-
Second Affiliated Hospital, School of Medicine,...Tongji Hospital; Qilu Hospital of Shandong University; First Hospital of China... and other collaboratorsRecruitingPembrolizumab | Non-small-lung-cell Cancer, NSCLCChina
-
Federal Budgetary Research Institution State Research...CompletedSmallpox | Monkeypox | Cowpox | Vaccinia Virus InfectionRussian Federation
-
Centre Hospitalier Universitaire DijonCompleted
-
Outi AikioCompletedPrematurity; Extreme | Low Birthweight, Extremely (999 Grams or Less)Finland
-
Massachusetts General HospitalCompletedDistal Radius Fracture | Finger StiffnessUnited States